Groundbreaking Recognition for ExThera Medical's Innovations
ExThera Medical has recently achieved a significant milestone by being awarded funding from the Medical Technology Enterprise Consortium (MTEC) to conduct an important randomized controlled trial. This trial aims to evaluate the efficacy of the Seraph 100 Microbind Affinity Blood Filter, a pioneering device in the field of hemoperfusion technology, specifically targeted at treating patients suffering from sepsis attributable to wound infections. The trial is set to unfold at a leading medical institution, emphasizing the collaboration between cutting-edge medical technology and clinical expertise.
The Vital Role of MTEC in Advancing Medical Technology
MTEC is a crucial public-private partnership authorized by the Department of Defense (DoD). It plays a pivotal role in fostering the development and implementation of innovative medical technologies with a special focus on enhancing the health and safety of military service members, veterans, and civilians. Sepsis has tragically emerged as a leading cause of mortality in individuals with combat-related injuries, making the development of effective medical interventions an absolute priority for the DoD.
Seraph 100: Transforming Sepsis Treatment
The Seraph 100 is a remarkable pathogen-agnostic filtration device designed to rapidly diminish the concentration of harmful pathogens in the bloodstream, thereby providing a lifeline for patients battling severe infections. Having received multiple Breakthrough Device Designations from the United States Food and Drug Administration (FDA), it stands out as a “First-In-Class” medical device. Under an Emergency Use Authorization from the FDA, hundreds of patients have already benefited from its capabilities in the U.S., and an ongoing multicenter randomized controlled trial is further validating its effectiveness for individuals experiencing pathogen-associated shock.
Commitment to Unmet Medical Needs
According to Erin Borger, the CEO of ExThera Medical, “The MTEC collaboration reinforces our commitment to address unmet medical needs identified by the U.S. DoD.” The overarching goal of this initiative is to expedite the availability of this groundbreaking device for military use, aimed at saving lives in the most challenging of environments.
Collaboration with Leading Medical Institutions
Dr. John A. Vanchiere, the Medical Director of the LSU Health Shreveport Clinical Trials Office, expressed enthusiasm regarding this collaboration, stating, "The chance to explore how medical devices can benefit patients, especially those risking their lives for their country, is invaluable to us.” Together, they aim to harness the potential of Seraph 100, not only to treat current patients but also to enhance healthcare availability in the future.
Anticipated Developments in the Trial
The MTEC trial has officially commenced and is on track to enroll up to 330 patients, with the first patients expected to be enrolled by late Q2 of the following year. This initiative showcases the proactive approach in addressing severe medical challenges and the collaborative effort involved in advancing healthcare technology.
About ExThera Medical Corporation
ExThera Medical Corporation is at the forefront of developing and commercializing advanced extracorporeal blood filtration devices. The flagship product, Seraph 100, is designed to eliminate a wide array of pathogens from the bloodstream, proving to be instrumental in various medical settings, including hospitals, clinics, and even battlefields. This technology confronts healthcare challenges posed by nosocomial and community-acquired infections and extends its capabilities to addressing injuries associated with pandemics and biological threats.
A Commitment to Global Health Initiatives
The Seraph 100 Microbind Affinity Blood Filter received CE Mark approval in 2019, affirming its availability in the EU for treating bloodstream infections. While it has not yet been cleared or approved by the FDA for any indication beyond the Emergency Use Authorization for COVID-19 patients, its role in clinical practice is expanding continuously.
Innovative Filtration Technology
As blood circulates through the Seraph 100, it encounters specialized beads featuring receptors that closely mimic those on human cells, which are often targeted by pathogens. This innovative technology ensures that harmful substances are swiftly captured and effectively removed from the bloodstream, focusing specifically on the pathogens causing infections while simultaneously eliminating harmful by-products generated from those pathogens.
Future Developments at ExThera Medical
In addition to its focus on the Seraph 100, ExThera Medical is also advancing the ONCObind Procedure Hemoperfusion Filter. This device, which is built on the same technological platform as the Seraph 100, aims to support cancer treatments, showcasing the company’s broad commitment to enhancing health outcomes across a spectrum of medical needs.
Frequently Asked Questions
What is the purpose of the MTEC-awarded trial?
The trial aims to assess the efficacy of the Seraph 100 in treating sepsis caused by wound infections through a randomized controlled study.
How does the Seraph 100 device work?
Seraph 100 filters pathogens from the bloodstream, rapidly reducing infection levels without adding substances to the blood.
Why is sepsis a critical issue in combat settings?
Sepsis is a leading cause of death in individuals with combat-related injuries, highlighting the need for effective medical treatments.
What are the expected outcomes of the trial?
The trial aims to enroll 330 patients, with the goal of demonstrating the clinical effectiveness of Seraph 100 in critical care scenarios.
What future advancements are planned by ExThera Medical?
ExThera Medical plans to develop the ONCObind Procedure, focusing on enhancing treatment options for cancer.
